Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT00729898

BIASP-3512

Details and patient eligibility

About

This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.

Enrollment: 243 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient with diabetes type 2 diabetes
• Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin
• Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient

Exclusion criteria

• Known or suspected allergy to study product(s) or related products
• Pregnancy, breast-feeding or intention of becoming pregnant within the next 6 months

Trial design

243 participants in 1 patient group

A

Treatment:

Drug: biphasic insulin aspart 30